JP2023542541A - Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレーター、並びに関連製品及び方法 - Google Patents

Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレーター、並びに関連製品及び方法 Download PDF

Info

Publication number
JP2023542541A
JP2023542541A JP2023518858A JP2023518858A JP2023542541A JP 2023542541 A JP2023542541 A JP 2023542541A JP 2023518858 A JP2023518858 A JP 2023518858A JP 2023518858 A JP2023518858 A JP 2023518858A JP 2023542541 A JP2023542541 A JP 2023542541A
Authority
JP
Japan
Prior art keywords
trifluoromethyl
amino
cyclohexyl
quinolin
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518858A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022067094A5 (https=
JP2023542541A5 (https=
Inventor
ラニアー マリオン
ベーム マーカス
ホアン リミング
マーティンボロー エスター
センツ マルコス
セルフリッジ ブランドン
イェーガー アダム
Original Assignee
エサイエント ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エサイエント ファーマシューティカルズ，インコーポレイティド filed Critical エサイエント ファーマシューティカルズ，インコーポレイティド
Publication of JP2023542541A publication Critical patent/JP2023542541A/ja
Publication of JPWO2022067094A5 publication Critical patent/JPWO2022067094A5/ja
Publication of JP2023542541A5 publication Critical patent/JP2023542541A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023518858A 2020-09-25 2021-09-24 Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレーター、並びに関連製品及び方法 Pending JP2023542541A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063083638P 2020-09-25 2020-09-25
US63/083,638 2020-09-25
US202163145407P 2021-02-03 2021-02-03
US63/145,407 2021-02-03
US202163211987P 2021-06-17 2021-06-17
US63/211,987 2021-06-17
PCT/US2021/052044 WO2022067094A1 (en) 2020-09-25 2021-09-24 Modulators of mas-related g-protein receptor x2 and related products and methods

Publications (3)

Publication Number Publication Date
JP2023542541A true JP2023542541A (ja) 2023-10-10
JPWO2022067094A5 JPWO2022067094A5 (https=) 2024-10-02
JP2023542541A5 JP2023542541A5 (https=) 2024-10-02

Family

ID=78302949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518858A Pending JP2023542541A (ja) 2020-09-25 2021-09-24 Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレーター、並びに関連製品及び方法

Country Status (11)

Country Link
US (2) US11919864B2 (https=)
EP (1) EP4217345A1 (https=)
JP (1) JP2023542541A (https=)
KR (1) KR20230097015A (https=)
CN (1) CN116406357A (https=)
AU (1) AU2021347360A1 (https=)
CA (1) CA3193207A1 (https=)
IL (1) IL301575A (https=)
MX (1) MX2023003476A (https=)
WO (1) WO2022067094A1 (https=)
ZA (1) ZA202304729B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512839A (ja) * 2022-03-30 2025-04-22 エサイエント ファーマシューティカルズ，インコーポレイティド Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレーターとしてのキノリン誘導体及び関連製品
WO2026009854A1 (ja) * 2024-07-01 2026-01-08 日本たばこ産業株式会社 ピリダジノン化合物及びその医薬用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542541A (ja) * 2020-09-25 2023-10-10 エサイエント ファーマシューティカルズ，インコーポレイティド Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレーター、並びに関連製品及び方法
EP4232042A1 (en) * 2020-10-21 2023-08-30 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x2 and related products and their use
CN115850250B (zh) * 2022-10-25 2025-12-23 南京师范大学 一种可控可视化的一氧化碳释放剂及其制备方法和应用
CN121532382A (zh) * 2023-07-13 2026-02-13 北京普祺医药科技股份有限公司 Mas相关g蛋白受体x2的拮抗剂及其用途
US20250084063A1 (en) 2023-08-18 2025-03-13 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
CN119504738A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为mrgprx2拮抗剂的化合物及其制备方法和应用
WO2025119372A2 (zh) * 2023-12-08 2025-06-12 武汉人福创新药物研发中心有限公司 Mrgprx2拮抗剂及用途
WO2025153014A1 (zh) * 2024-01-17 2025-07-24 武汉人福创新药物研发中心有限公司 Mas相关g蛋白受体x2拮抗剂及用途
US20250243208A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
WO2025223036A1 (zh) * 2024-04-23 2025-10-30 凯复(苏州)生物医药有限公司 Mrgprx2拮抗剂、包含其的药物组合物及其用途
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026037254A1 (zh) * 2024-08-10 2026-02-19 杭州英创医药科技有限公司 作为mrgprx2拮抗剂的化合物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074341A1 (en) * 2001-03-19 2002-09-26 Nippon Shinyaku Co., Ltd. Antipruritics
JP2005501848A (ja) * 2001-08-15 2005-01-20 アイコス コーポレイション ２ｈ−フタラジン−１−オンおよびその使用方法
US20050054850A1 (en) * 2003-02-28 2005-03-10 Chengde Wu Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
JP2006124387A (ja) * 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
JP2006519258A (ja) * 2003-02-28 2006-08-24 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ｉｉ受容体拮抗薬
JP2007517868A (ja) * 2004-01-07 2007-07-05 アストラゼネカ アクチボラグ 治療薬ｉ
JP2012531438A (ja) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびその使用
JP2016506965A (ja) * 2013-02-01 2016-03-07 ウェルスタット セラピューティクス コーポレイション 抗炎症、抗真菌、抗寄生生物及び抗癌活性を有するアミン化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853833A1 (en) * 2011-11-08 2013-05-16 Arena Pharmaceuticals, Inc. Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
JP2023542541A (ja) * 2020-09-25 2023-10-10 エサイエント ファーマシューティカルズ，インコーポレイティド Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレーター、並びに関連製品及び方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074341A1 (en) * 2001-03-19 2002-09-26 Nippon Shinyaku Co., Ltd. Antipruritics
JP2005501848A (ja) * 2001-08-15 2005-01-20 アイコス コーポレイション ２ｈ−フタラジン−１−オンおよびその使用方法
US20050054850A1 (en) * 2003-02-28 2005-03-10 Chengde Wu Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
JP2006519258A (ja) * 2003-02-28 2006-08-24 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ｉｉ受容体拮抗薬
JP2007517868A (ja) * 2004-01-07 2007-07-05 アストラゼネカ アクチボラグ 治療薬ｉ
JP2006124387A (ja) * 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
JP2012531438A (ja) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびその使用
JP2016506965A (ja) * 2013-02-01 2016-03-07 ウェルスタット セラピューティクス コーポレイション 抗炎症、抗真菌、抗寄生生物及び抗癌活性を有するアミン化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512839A (ja) * 2022-03-30 2025-04-22 エサイエント ファーマシューティカルズ，インコーポレイティド Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレーターとしてのキノリン誘導体及び関連製品
WO2026009854A1 (ja) * 2024-07-01 2026-01-08 日本たばこ産業株式会社 ピリダジノン化合物及びその医薬用途

Also Published As

Publication number Publication date
IL301575A (en) 2023-05-01
KR20230097015A (ko) 2023-06-30
US20240336570A1 (en) 2024-10-10
WO2022067094A1 (en) 2022-03-31
EP4217345A1 (en) 2023-08-02
AU2021347360A9 (en) 2024-02-08
CA3193207A1 (en) 2022-03-31
US11919864B2 (en) 2024-03-05
US20230065217A1 (en) 2023-03-02
MX2023003476A (es) 2023-06-22
AU2021347360A1 (en) 2023-05-25
US12275707B2 (en) 2025-04-15
CN116406357A (zh) 2023-07-07
ZA202304729B (en) 2025-10-29

Similar Documents

Publication Publication Date Title
JP2023542541A (ja) Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレーター、並びに関連製品及び方法
WO2022140520A1 (en) Modulators of mas-related g-protein receptor x2 and related products and methods
JP2023546912A (ja) Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレータ及び関連製品並びにその使用
US11952346B2 (en) Modulators of mas-related G-protein receptor X2 and related products and methods
CA2952692C (en) Substituted imidazo[1,2b]pyridazine compounds
ES2770693T3 (es) Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
JP2025512839A (ja) Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレーターとしてのキノリン誘導体及び関連製品
WO2010056758A1 (en) Quinazoline derivatives as kinase inhibitors
JP2010503701A (ja) 増殖性疾患の治療に有用なキナーゼ阻害剤
EA036058B1 (ru) Ингибитор jak
TW202409036A (zh) Parg抑制劑
AU2023378452A1 (en) Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof
CN119255992A (zh) 杂环衍生物及其组合物和应用
RU2841536C1 (ru) Модуляторы mas-связанного рецептора g-белка x2 и связанные с ними продукты и способы
WO2024092222A1 (en) Modulators of mas-related g-protein receptor d and related products and methods
EP4543543A1 (en) Triazole derivatives as modulators of mas-related g-protein receptor d
BR122025025337A2 (pt) Processos, intermediários e usos para preparação de derivados de piridina de tetra-hidrotieno

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260113